The Food and Drug Administration (FDA) will sharply restrict the use of two monoclonal antibody treatments according to a new report by the Washington Post.
According to WaPo, the Biden Administration is expected to halt distribution of monoclonal antibody treatments made by Regeneron Pharmaceuticals and Eli Lilly because they are ‘ineffective against Omicron.’
The Washington Post reported:
The Food and Drug Administration is poised as soon as Monday to restrict two monoclonal antibodies, saying the covid-19 treatments should not be employed in any states because they are ineffective against the dominant omicron variant, according to two senior administration health officials.
As a result, the Biden administration will pause distribution of the therapies, manufactured by Regeneron Pharmaceuticals and Eli Lilly, to the states.
“We want to make sure that patients get treatments that are effective, not treatments that don’t work,” said one of the officials, who spoke on the condition of anonymity to describe internal discussions.
The FDA action will involve revising the emergency use authorizations for the monoclonal antibodies. The agency will not revoke the authorizations in case the treatments become useful against a future coronavirus variant.
The Centers for Disease Control and Prevention has estimated that more than 99 percent of current covid-19 cases are caused by omicron.
Biden administration officials noted that several therapies remain effective against omicron, including sotrovimab — a monoclonal antibody made by GlaxoSmithKline and Vir Biotechnology — and antiviral pills by Pfizer and by Merck and its partner, Ridgeback Biotherapeutics.
In addition, the use of the antiviral drug remdesivir as an outpatient therapy recently got the green light from regulators. However, some of the treatments, including the Pfizer pill and sotrovimab, are experiencing supply shortages.
Democrat death panels?
Earlier this month Project Veritas released never before seen military documents regarding the origins of Covid-19, gain-of-function research, vaccines, potential treatments and the government’s effort to conceal everything.
The documents contained evidence that Ivermectin and hydroxychloroquine were both effective in treating the coronavirus because they both inhibited the viral replication that spread the spike protein around the body.
There have now been 67 Ivermectin COVID-19 controlled studies that show a 67% improvement in COVID patients.
There have been 298 Hydroxychloroquine studies that show a 64% improvement in patients for COVID-19 patients.
Ivermectin, HCQ, and life-saving monoclonal antibody treatments are going to be restricted while ineffective Covid vaccines and anti-viral pills made by Pfizer (Pfizermectin) are distributed.
The post FDA to Sharply Restrict Use of Two Monoclonal Antibody Treatments appeared first on The Gateway Pundit.
